University of Kansas Medical Center Research Institute Inc

1. Astellas Pharma Inc $2,519,718 877 payments
2. Genentech, Inc. $2,121,972 183 payments
3. AbbVie, Inc. $1,472,433 189 payments
4. Pfizer Inc. $1,428,363 155 payments
5. Intercept Pharmaceuticals, Inc. $1,008,239 111 payments
6. Regeneron Pharmaceuticals, Inc. $936,632 265 payments
7. Boston Scientific Corporation $917,543 256 payments
8. Horizon Therapeutics plc $456,975 5 payments
9. Aveo Pharmaceuticals, Inc. $423,473 187 payments
10. Pharmacyclics LLC, An AbbVie Company $417,883 184 payments

1. A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation $2,519,718 877 payments
2. A Phase 1B2 Openlabel Study of Pf07901801 in Combination With Glofitamab After A Fixed Single Dose of Obinutuzumab in Participants With Relapsedrefractory Diffuse Large B Cell Lymphoma Not Eligible for Stem Cell Transplantation $587,609 25 payments
3. M15-566 $496,138 28 payments
4. A Phase III Study to Evaluate the Efficacy and Safety of Fenebrutinib in Adults With Progressive Ms $472,347 25 payments
5. Proof of concept study of GYM329 in FSHD $424,890 24 payments
6. A Phase 2B Efficacy Safety Trial of Prasinezumab in Patients With Early Parkinson S Disease $373,342 25 payments
7. Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) $323,067 163 payments
8. A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. $309,130 40 payments
9. 1009742 $290,695 21 payments
10. Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) $284,791 44 payments

1. Patient care $188,396 27 payments
2. Other $161,166 45 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.